➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Colorcon
AstraZeneca
McKesson
Baxter

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CC-122

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CC-122?

CC-122 is an investigational drug.

There have been 13 clinical trials for CC-122. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Large B-Cell, Diffuse, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are Celgene Corporation, Celgene, and Bristol-Myers Squibb.

There are thirty-nine US patents protecting this investigational drug and four hundred and twenty-seven international patents.

Recent Clinical Trials for CC-122
TitleSponsorPhase
Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaBristol-Myers SquibbPhase 2
Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaCelgene CorporationPhase 2
Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaH. Lee Moffitt Cancer Center and Research InstitutePhase 2

See all CC-122 clinical trials

Clinical Trial Summary for CC-122

Top disease conditions for CC-122
Top clinical trial sponsors for CC-122

See all CC-122 clinical trials

US Patents for CC-122

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-122   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
CC-122   Start Trial Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies Celgene Corporation (Summit, NJ)   Start Trial
CC-122   Start Trial Formulations of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione Celgene Corporation (Summit, NJ)   Start Trial
CC-122   Start Trial Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast Celgene Corporation (Summit, NJ)   Start Trial
CC-122   Start Trial Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases CELGENE CORPORATION (Summit, NJ)   Start Trial
CC-122   Start Trial Methods to induce targeted protein degradation through bifunctional molecules Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CC-122

Drugname Country Document Number Estimated Expiration Related US Patent
CC-122 European Patent Office EP3313818 2035-06-26   Start Trial
CC-122 Japan JP2018527302 2035-06-26   Start Trial
CC-122 World Intellectual Property Organization (WIPO) WO2016210262 2035-06-26   Start Trial
CC-122 Australia AU2015305449 2034-08-22   Start Trial
CC-122 Brazil BR112017003620 2034-08-22   Start Trial
CC-122 Canada CA2958867 2034-08-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Colorcon
AstraZeneca
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.